top of page

Antibody-drug conjugates at #ASCO23 with Seagen’s David Epstein

Seagen CEO David Epstein talks about moving antibody-drug conjugates into broader indications at #ASCO23.



Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page